Articles NewsFlow La Cote de l’or et de l’argent Market Briefing

Recevez notre Marketbriefing

overtheedge
Membre depuis mai 2012
680 commentaires - suivi par 6 personnes

6 abonnées

A laissé un commentaire sur l'article :

Immuno-Oncology Promises Continued Wealth and Health: LifeTech Capital's Stephen Dunn - The Life Sciences Report -

Who is going to pay these prices for the treatment?
Perhaps the 1%ers might have the income stream, but what percentage of them will need it?
Now factor in the length of drug patent rights.

All I see is a pump and dump.
The majors eventually buy the minors to acquire all the research and then write the cost off against taxes.
Never argue with success.

Commenté il y a 3489 jours

envoyer

Début de l'article :Immuno-oncology—disabling cancer's defenses so that a patient's own immune system can seek it out and destroy it—took center stage in the drug development world in 2014. Stephen Dunn of LifeTech Capital believes that preeminence will continue in 2015, bolstered by new drug approvals, new targets and new combination immunotherapies that increase potency. In this interview with The Life Sciences Report, Dunn outlines how companies large and small are leveraging these therapies, and where investors... Lire la suite

Répondre à ce commentaire

Vous devez être connecté pour commenter un article

8000 caractères max.

connectez-vous ou inscrivez-vous

	Nos flux RSS		24hGold Mobile
	Gold Data Center		Convertisseur Or Argent
	Pièces d'or sur eBay		Pièces d'argent sur eBay
	Minières : outils techniques		Minières : outils d'analyse fondamentale